NNVC News

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference Ready to Announce with Confidence?

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Form 8-K

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres